Voyager Therapeutics Q4 2023 GAAP EPS $1.25 Beats $(0.29) Estimate, Sales $90.06M Beat $20.64M Estimate
Portfolio Pulse from Benzinga Newsdesk
Voyager Therapeutics (NASDAQ:VYGR) reported Q4 2023 earnings of $1.25 per share, surpassing the $(0.29) estimate, with sales of $90.06M also beating the $20.64M estimate. This represents a significant increase over the previous year's sales of $(1.55M).
February 28, 2024 | 9:27 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Voyager Therapeutics reported a significant beat on both EPS and sales estimates for Q4 2023, with a dramatic increase in sales compared to the previous year.
The substantial beat on both earnings per share and sales estimates, coupled with a significant year-over-year sales increase, is likely to positively impact investor sentiment and the stock price in the short term. The magnitude of the beat and the growth rate are indicators of strong financial health and operational efficiency, which are key drivers of stock performance.
CONFIDENCE 90
IMPORTANCE 95
RELEVANCE 100